CRC Screening Toolkit for Diabetes
Trial Summary
What is the purpose of this trial?
This mixed methods study evaluates the effectiveness and feasibility of a multi-level (patient, team, organizations) intervention to optimize CRC screening for patients with diabetes in primary care safety-net settings.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Targeted CRC Screening Toolkit for diabetes?
The research highlights that colorectal cancer (CRC) screening is effective in reducing mortality and that tailored risk information can improve screening rates. This suggests that a targeted CRC screening toolkit, which likely includes personalized risk assessments, could be effective in increasing screening adherence and outcomes.12345
Is the CRC Screening Toolkit for Diabetes safe for humans?
How does this treatment for colorectal cancer screening differ from others?
Research Team
Denalee O'Malley, PhD
Principal Investigator
Rutgers Robert Wood Johnson Medical School; Rutgers Cancer Institute of New Jersey
Eligibility Criteria
This trial is for people aged 50-74 with diabetes who are overdue for colorectal cancer (CRC) screening. They must not be up-to-date with CRC tests and can join even if they've started but not finished screening over six months ago. It's not open to those with conditions like past CRC, inflammatory bowel disease, or renal failure.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Implementation
Implementation of targeted CRC screening strategies for patients with diabetes in safety-net primary care settings
Follow-up
Participants are monitored for safety and effectiveness after implementation
Treatment Details
Interventions
- Targeted CRC Screening Toolkit
Find a Clinic Near You
Who Is Running the Clinical Trial?
Rutgers, The State University of New Jersey
Lead Sponsor
National Cancer Institute (NCI)
Collaborator